In CVD,
There's no time to wait

The disheartening reversal in CVD trends

Despite the availability of lipid-lowering therapies (LLTs), cardiovascular disease (CVD) remains the leading cause of death globally—a trend that is expected to continue.1-3

In the US between 2019 and 2022, CVD age-adjusted mortality rates (AAMR) increased 9%, reversing the decreased mortality rate trend observed since 2010 and undoing nearly a decade of progress.4

Age-adjusted mortality rates (AAMR) due to CVD increased in the US between 2019 and 20224

CVD mortality rates began rising in 2010 after decades of steady decline.5

CVD mortality trends for US males and females, 1980 to 20205

Reprinted from Tsao CW, et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93-e621.

By 2050 >184 million US adults are expected to be affected by CVD and hypertension, including ≈27 million with coronary heart disease (CHD) and ≈19 million with stroke.2,6

ASCVD can present differently based on the vascular bed affected3

Myocardial
infarction8
Unstable
angina8
Ischemic
stroke8
Peripheral arterial
disease8

Prevention and effective management of ASCVD is paramount to public health.3

Although more patients are surviving their first CVD event, they are at high risk of recurrence.9

Each year in the US,

≈605000

new heart
attacks occur10

≈200000

recurrent heart
attacks occur10

≈170000

of these heart attacks

are silent, without
significant symptoms10

Exploring the link between LDL-C and ASCVD

Low-density lipoprotein cholesterol (LDL-C) is strongly and linearly associated with a dose-dependent increase in risk of ASCVD, as demonstrated across multiple genetic, observational, and controlled studies.11

LDL-C is strongly and linearly associated with a dose-dependent increase in risk of incident ASCVD events11
Reducing levels of circulating LDL-C is critical to halting atherosclerotic plaque build-up and reducing cardiovascular risk.11

Learn about LDL-C goals and treatment recommendations

explore

References: 1. World Health Organization. Cardiovascular diseases (CVDs). Accessed July 24, 2024. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) 2. Joynt Maddox KE, Elkind MSV, Aparicio HJ, et al. Forecasting the burden of cardiovascular disease and stroke in the United States through 2050—prevalence of risk factors and disease: a presidential advisory from the American Heart Association; American Heart Association. Circulation. 2024;150(4):e65-e88. 3. Makover ME, Shapiro MD, Toth PP. There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: a review of current practice and recommendations for improved effectiveness. Am J Prev Cardiol. 2022;12:100371. 4. Woodruff RC, Tong X, Khan SS, et al. Trends in cardiovascular disease mortality rates and excess deaths, 2010-2022. Am J Prev Med. 2024;66(4):582-589. 5. Tsao CW, Aday AW, Almarzooq ZI, et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93-e621. 6. Joynt Maddox KE, Elkind MSV, Aparicio HJ, et al; American Heart Association. Forecasting the burden of cardiovascular disease and stroke in the United States through 2050—prevalence of risk factors and disease: a presidential advisory from the American Heart Association; American Heart Association. Supplemental Material. Circulation. 2024;150(4):e65-e88. 7. Vasan RS, Enserro DM, Xanthakis V, Beiser AS, Seshadri S. Temporal trends in the remaining lifetime risk of cardiovascular disease among middle-aged adults across six decades: the Framingham Study. Circulation. 2022;145(17):1324-1338. 8. American Diabetes Association. 9. Cardiovascular disease and risk management. Diabetes Care. 2017;40(suppl 1):S75-S87. 9. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188. 10. Martin SS, Aday AW, Almarzooq ZI, et al. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2024;149(8):e347-e913. 11. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472.